Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Löwenberg

Showing results (1-10 of 126) with videos related to

Pageof 13
Sort By:
Current Opinion in Drug Discovery & Development|September 6, 2007
Proximal signaling molecules as potential targets for anti-inflammatory therapyMark Löwenberg
Current Gastroenterology Reports|June 3, 2015
Next-Generation Therapeutics for IBDMark Löwenberg, Geert D'Haens
Current Gastroenterology Reports|January 15, 2013
Novel targets for inflammatory bowel disease therapeuticsMark Löwenberg, Geert D'Haens
Current Drug Targets|June 6, 2012
Mucosal healing in Crohn's disease: relevance for clinical outcomesMark Löwenberg, Geert D'Haens
Drugs|August 16, 2006
Biological therapy in the management of recent-onset Crohn's disease: why, when and how?Mark Löwenberg, Maikel Peppelenbosch, Daniel Hommes
World Journal of Clinical Cases|February 17, 2016
Herpes simplex induced necrotizing tonsillitis in an immunocompromised patient with ulcerative colitisLaura Jansen, Xander G Vos, Mark Löwenberg
Expert Review of Clinical Pharmacology|July 16, 2019
Therapeutic drug monitoring-based dosing of TNF inhibitors in inflammatory bowel disease: the way forward?Anne S Strik, Sophie E Berends, Mark Löwenberg
Clinical and Experimental Gastroenterology|April 22, 2014
Management of Crohn's disease in poor responders to adalimumabNanne Kh de Boer, Mark Löwenberg, Frank Hoentjen
Clinical and Experimental Gastroenterology|March 21, 2014
Golimumab for the treatment of ulcerative colitisMark Löwenberg, Nanne Kh de Boer, Frank Hoentjen
Clinical Case Reports|December 3, 2019
Hemolytic anemia after switching from infliximab originator to biosimilar CT-P13 in a patient with inflammatory bowel disease: A case reportAnne S Strik, Geert R D'Haens, Mark Löwenberg
Pageof 13

Showing results (1-10 of 126) with videos related to

Sort By:
Pageof 13
Current Opinion in Drug Discovery & Development|September 6, 2007
Proximal signaling molecules as potential targets for anti-inflammatory therapyMark Löwenberg
Current Gastroenterology Reports|June 3, 2015
Next-Generation Therapeutics for IBDMark Löwenberg, Geert D'Haens
Current Gastroenterology Reports|January 15, 2013
Novel targets for inflammatory bowel disease therapeuticsMark Löwenberg, Geert D'Haens
Current Drug Targets|June 6, 2012
Mucosal healing in Crohn's disease: relevance for clinical outcomesMark Löwenberg, Geert D'Haens
Drugs|August 16, 2006
Biological therapy in the management of recent-onset Crohn's disease: why, when and how?Mark Löwenberg, Maikel Peppelenbosch, Daniel Hommes
World Journal of Clinical Cases|February 17, 2016
Herpes simplex induced necrotizing tonsillitis in an immunocompromised patient with ulcerative colitisLaura Jansen, Xander G Vos, Mark Löwenberg
Expert Review of Clinical Pharmacology|July 16, 2019
Therapeutic drug monitoring-based dosing of TNF inhibitors in inflammatory bowel disease: the way forward?Anne S Strik, Sophie E Berends, Mark Löwenberg
Clinical and Experimental Gastroenterology|April 22, 2014
Management of Crohn's disease in poor responders to adalimumabNanne Kh de Boer, Mark Löwenberg, Frank Hoentjen
Clinical and Experimental Gastroenterology|March 21, 2014
Golimumab for the treatment of ulcerative colitisMark Löwenberg, Nanne Kh de Boer, Frank Hoentjen
Clinical Case Reports|December 3, 2019
Hemolytic anemia after switching from infliximab originator to biosimilar CT-P13 in a patient with inflammatory bowel disease: A case reportAnne S Strik, Geert R D'Haens, Mark Löwenberg
Pageof 13